Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. Shares of ph...
Streetwise Reports | December 13, 2019 |

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
Marc Davis | September 1, 2020 |

Buzz on the Bullboards: Finding Diamonds in the Rough

While the markets were rocked at the end of January by the Wuhan coronavirus, the beginning of February has seen a return to the non-stop climb that began in last fall. Once we break things down by sector, however, the picture becomes murkier. The cannabis sector continues...
Omri Wallach | February 5, 2020 |

A Topical Solution for Chronic Pain

Pain impedes the life of millions around the world, and the market for topical creams to treat this pain is growing at an accelerated rate as people choose to treat pain directly vs ingesting pain killers. Some analysts, such as those at Allied Market Research, project that ...
Jonathon Brown | May 2, 2022 |

A Look into the Future of Chronic Pain Management

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief solutions — particularly through its slow-release injection technology. This cutting-edge approach delivers synthetic Cannabidi...
Research | 5 days ago |

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. Specialty pharmaceutical company Baudax Bio Inc. (BXRX:N...
Streetwise Reports | February 24, 2020 |

FDA Approval of Biopharma's Pain Drug Expected This Year

The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. In a Feb. 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that the U.S. ...
Streetwise Reports | February 20, 2020 |

Developer of Cannabinoid-Based Drugs to Resume Cancer Pain Trial

Calling this latest development "excellent news," Paradigm Capital has raised its target price on the company's stock. In an April 9 research note, analyst Rahul Sarugaser reported that Paradigm Capital raised its target price on Tetra Bio-Pharma Inc. (TBP:TSX.V; TBPMF...
Streetwise Reports | April 18, 2019 |

Top Pick Status Given to Small-Cap with Pain Drug Candidate

The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. In a July 10 research note, analyst Douglas Loe reported that Echelon Wealth Partners bestowed Top Pick status on Antibe Therapeutics Inc. (ATE:TSX.V...
Streetwise Reports | July 19, 2019 |

How to Buy Penny Stocks

A "penny stock" (also known as a micro-cap stock) is a publicly-traded stock with an extremely low price per share – usually under five dollars and often less than a dollar (hence the name "penny" stock). They are typically issued by small, less-established companies. Be ...
Stockhouse Editorial | July 24, 2019 |
1 2 3 4 5 6 7 8 9 10 ...